

# NEW ZEALAND DATA SHEET

## 1. PRODUCT NAME

Polivy<sup>®</sup> (polatuzumab vedotin) 140 mg, powder for injection.

Polivy<sup>®</sup> (polatuzumab vedotin) 30 mg, powder for injection

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Polivy is available as a single-use vial containing 30 mg or 140 mg of polatuzumab vedotin.

Polatuzumab vedotin is a CD79b-targeted antibody-drug conjugate that preferentially binds with high affinity and selectivity to CD79b, a cell surface component of the B-cell receptor. Polatuzumab vedotin is produced by recombinant DNA technology in Chinese Hamster Ovary cells.

For the full list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

Powder for injection.

Polivy is a preservative-free white to greyish-white lyophilised powder supplied in single-dose vials that deliver 30 mg or 140 mg of polatuzumab vedotin. Upon reconstitution Polivy concentrate contains 20 mg/mL of polatuzumab vedotin for intravenous infusion (refer to section 4.2 *Dose and method of administration, Method of administration*).

## 4. CLINICAL PARTICULARS

### 4.1 *Therapeutic indications*

Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma.

Polivy in combination with bendamustine and rituximab is indicated for the treatment of previously treated adult patients with diffuse large B-cell lymphoma who are not candidates for hematopoietic stem cell transplant.

### 4.2 *Dose and method of administration*

#### **General**

Substitution by any other biological medicinal product requires the consent of the prescribing physician.

In order to prevent medication errors, it is important to check the vial labels to ensure that the drug being prepared and administered is Polivy.

Polivy therapy should only be administered under the supervision of a healthcare professional experienced in the treatment of cancer patients.

Polivy must be reconstituted and diluted using aseptic techniques under the supervision of a healthcare professional. Polivy must be administered as an intravenous infusion through a dedicated infusion line equipped with a sterile, non-pyrogenic, low-protein binding in-line or add-on filter (0.2 or 0.22  $\mu\text{m}$  pore size) and catheter (see 4.2 *Dose and method of administration, Method of administration*). Do not administer as an IV push or bolus.

For information on rituximab, bendamustine, cyclophosphamide, doxorubicin, or prednisone, refer to their respective full prescribing information. Refer to Table 2 for dose modification recommendations for neutropenia and thrombocytopenia.

## **Dose**

### **Diffuse large B-cell lymphoma (DLBCL)**

#### *Previously untreated patients:*

The recommended dose of Polivy is 1.8 mg/kg given as an intravenous infusion every 21 days for 6 cycles in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP). Polivy, rituximab, cyclophosphamide, and doxorubicin can be administered in any order on Day 1 after the administration of prednisone. Prednisone is administered on Days 1–5 of each cycle. Cycles 7 and 8 consist of rituximab as monotherapy.

#### *Previously treated patients:*

The recommended dose of Polivy is 1.8 mg/kg given as an intravenous infusion every 21 days in combination with bendamustine and rituximab for 6 cycles. Polivy, bendamustine, and rituximab can be administered in any order on Day 1 of each cycle. The recommended dose of bendamustine is 90 mg/m<sup>2</sup>/day on Day 1 and 2 when administered with Polivy and rituximab.

#### *Previously untreated and treated patients:*

If not already premedicated, administer premedication with an antihistamine and anti-pyretic to patients prior to administration of Polivy. The initial dose of Polivy should be administered as a 90-minute intravenous infusion. Patients should be monitored for infusion-related reactions during the infusion and for at least 90 minutes following completion of the initial dose. If the prior infusion was well tolerated, the subsequent dose of Polivy may be administered as a 30-minute infusion and patients should be monitored during the infusion and for at least 30 minutes after completion of the infusion.

## **Duration of Treatment**

The recommended duration of treatment is for 6 cycles.

## **Delayed or Missed Doses**

If a planned dose of Polivy is missed, it should be administered as soon as possible and the schedule of administration should be adjusted to maintain a 21-day interval between doses.

## **Dose Modifications**

There are different possible dose modifications for Polivy in patients with previously untreated DLBCL and those who are previously treated (see Table 1 and Table 2).

The infusion rate of Polivy should be slowed or interrupted if the patient develops an infusion-related reaction. Discontinue Polivy immediately and permanently if the patient experiences a life-threatening reaction.

For dose modifications to manage peripheral neuropathy see Table 1.

**Table 1 Polivy dose modifications for peripheral neuropathy**

Indication	Severity on Day 1 of any cycle	Dose modification
Previously untreated DLBCL	Grade 2 <sup>a</sup>	<p>Sensory neuropathy:</p> <ul style="list-style-type: none"> <li>● Reduce Polivy to 1.4 mg/kg.</li> <li>● If Grade 2 persists or recurs at Day 1 of a future cycle, reduce Polivy to 1.0 mg/kg.</li> <li>● If already at 1.0 mg/kg and Grade 2 occurs at Day 1 of a future cycle, discontinue Polivy.</li> </ul> <p>Motor neuropathy:</p> <ul style="list-style-type: none"> <li>● Hold Polivy dosing until improvement to ≤ Grade 1.</li> <li>● Restart Polivy at the next cycle at 1.4 mg/kg.</li> <li>● If already at 1.4 mg/kg and Grade 2 occurs at Day 1 of future cycle, hold Polivy dosing until improvement to ≤ Grade 1. Restart Polivy at 1.0 mg/kg.</li> <li>● If already at 1.0 mg/kg and Grade 2 occurs at Day 1 of future cycle, discontinue Polivy.</li> </ul> <p>If concurrent sensory and motor neuropathy occur, follow the most severe restriction recommendation above.</p>
	Grade 3 <sup>a</sup>	<p>Sensory neuropathy:</p> <ul style="list-style-type: none"> <li>● Hold Polivy dosing until improvement to ≤ Grade 2.</li> <li>● Reduce Polivy to 1.4 mg/kg.</li> <li>● If already at 1.4 mg/kg, reduce Polivy to 1.0 mg/kg. If already at 1.0 mg/kg, discontinue Polivy.</li> </ul> <p>Motor neuropathy:</p> <ul style="list-style-type: none"> <li>● Hold Polivy dosing until improvement to ≤ Grade 1.</li> <li>● Restart Polivy at the next cycle at 1.4 mg/kg.</li> <li>● If already at 1.4 mg/kg and Grade 2–3 occurs, hold Polivy dosing until improvement to ≤ Grade 1. Restart Polivy at 1.0 mg/kg.</li> <li>● If already at 1.0 mg/kg and Grade 2–3 occurs, discontinue Polivy.</li> </ul> <p>If concurrent sensory and motor neuropathy occur, follow the most severe restriction recommendation above.</p>

	Grade 4	Discontinue Polivy.
Previously treated DLBCL	Grade 2-3	Hold Polivy dosing until improvement to $\leq$ Grade 1.  If recovered to Grade $\leq$ 1 on or before Day 14, restart Polivy at a permanently reduced dose of 1.4 mg/kg.  If a prior dose reduction to 1.4 mg/kg has occurred, discontinue Polivy.  If not recovered to Grade $\leq$ 1 on or before Day 14, discontinue Polivy.
	Grade 4	Discontinue Polivy.

<sup>a</sup>R-CHP may continue to be administered.

For dose modifications for myelosuppression see Table 2.

**Table 2 Polivy, chemotherapy, and rituximab dose modifications for myelosuppression**

Indication	Severity on Day 1 of any cycle	Dose modification
Previously untreated DLBCL	Grade 3–4 Neutropenia	Hold all treatment until ANC recovers to $>1 \times 10^9/L$ .  If ANC recovers to $>1 \times 10^9/L$ on or before Day 7 of the treatment cycle, resume all treatment without any additional dose reductions.  If ANC recovers to $1 \times 10^9/L$ after Day 7: <ul style="list-style-type: none"> <li>● resume all treatment; consider a dose reduction of cyclophosphamide and/or doxorubicin by 25–50%</li> <li>● if cyclophosphamide and/or doxorubicin are already reduced by 25%, consider reducing one or both agents to 50%</li> </ul>

	Grade 3–4 Thrombocytopenia	<p>Hold all treatment until platelets recover to <math>&gt;75 \times 10^9/L</math>.</p> <p>If platelets recover to <math>&gt;75 \times 10^9/L</math> on or before Day 7, resume all treatment without any additional dose reductions.</p> <p>If platelets recover to <math>&gt;75 \times 10^9/L</math> after Day 7:</p> <ul style="list-style-type: none"> <li>● resume all treatment; consider a dose reduction of cyclophosphamide and/or doxorubicin by 25–50%</li> <li>● if cyclophosphamide and/or doxorubicin are already reduced by 25%, consider reducing one or both agents to 50%</li> </ul>
Previously treated DLBCL	Grade 3-4 Neutropenia <sup>a</sup>	<p>Hold all treatment until ANC recovers to <math>&gt;1 \times 10^9/L</math>.</p> <p>If ANC recovers to <math>&gt;1 \times 10^9/L</math> on or before Day 7, resume all treatment without any additional dose reductions.</p> <p>If ANC recovers to <math>&gt;1 \times 10^9/L</math> after Day 7:</p> <ul style="list-style-type: none"> <li>● restart all treatment, with a dose reduction of bendamustine from <math>90 \text{ mg/m}^2</math> to <math>70 \text{ mg/m}^2</math> or <math>70 \text{ mg/m}^2</math> to <math>50 \text{ mg/m}^2</math></li> <li>● if a bendamustine dose reduction to <math>50 \text{ mg/m}^2</math> has already occurred, discontinue all treatment</li> </ul>
	Grade 3-4 Thrombocytopenia <sup>a</sup>	<p>Hold all treatment until platelets recover to <math>&gt;75 \times 10^9/L</math>.</p> <p>If platelets recover to <math>&gt;75 \times 10^9/L</math> on or before Day 7, resume all treatment without any additional dose reductions.</p> <p>If platelets recover to <math>&gt;75 \times 10^9/L</math> after Day 7:</p> <ul style="list-style-type: none"> <li>● restart all treatment, with a dose reduction of bendamustine from <math>90 \text{ mg/m}^2</math> to <math>70 \text{ mg/m}^2</math> or <math>70 \text{ mg/m}^2</math> to <math>50 \text{ mg/m}^2</math></li> <li>● if a bendamustine dose reduction to <math>50 \text{ mg/m}^2</math> has already occurred, discontinue all treatment</li> </ul>

<sup>a</sup>If primary cause is due to lymphoma, the dose of bendamustine may not need to be reduced.

## Special populations

### Paediatric populations

The safety and efficacy of Polivy in children and adolescents (<18 years) has not been established (see section 5.2 *Pharmacokinetics in Special Populations*).

### Elderly

No dose adjustment of Polivy is required in patients  $\geq 65$  years of age (see section 5.2 *Pharmacokinetics in Special Populations*).

### Renal Impairment

No dose adjustment of Polivy is required in patients with creatinine clearance (CrCL)  $\geq 30$  mL/min. A recommended dose has not been determined for patients with CrCL  $< 30$  mL/min (see section 5.2 *Pharmacokinetics in Special Populations*).

### Hepatic Impairment

The administration of Polivy in patients with moderate or severe hepatic impairment (total bilirubin greater than  $1.5 \times$  upper limit of normal [ULN]) should be avoided.

No dose adjustment is required for patients with mild hepatic impairment [total bilirubin greater than ULN and less than or equal to  $1.5 \times$ ULN or aspartate transaminase AST greater than ULN] (see section 5.2 *Pharmacokinetics in Special Populations*).

## **Method of Administration**

Polivy must be reconstituted using sterile water for injection and diluted into an IV infusion bag containing 0.9% sodium chloride, 0.45% sodium chloride, or 5% dextrose by a healthcare professional prior to administration.

Use aseptic technique for reconstitution and dilution of Polivy. Appropriate procedures for the preparation of antineoplastic products should be used.

The reconstituted product contains no preservative and is intended for single-dose usage only. Discard any unused portion.

A dedicated infusion line equipped with a sterile, non-pyrogenic, low-protein binding in-line or add-on filter (0.2 or 0.22  $\mu\text{m}$  pore size) and catheter must be used to administer diluted Polivy.

For instructions on reconstitution and dilution of the product before administration, see section 6.6 *Special Precautions for Disposal and Other Handling*.

## **4.3 Contraindications**

Polivy is contraindicated in patients with a known hypersensitivity to polatuzumab vedotin or any of the excipients.

## **4.4. Special Warnings And Precautions For Use**

In order to improve traceability of biological medicinal products, the trade name and the batch number of the administered product should be clearly recorded (or stated) in the patient file.

## **Myelosuppression**

Serious and severe neutropenia and febrile neutropenia have been reported in patients treated with Polivy as early as the first cycle of treatment (see section 4.8 *Undesirable Effects*). Prophylactic G-CSF administration should be considered. Grade 3 or 4 thrombocytopenia or anaemia can also occur with Polivy (see section 4.8 *Undesirable Effects*). Complete blood counts should be monitored prior to each dose of Polivy. More frequent lab monitoring and/or Polivy delays or discontinuation should be considered in patients with Grade 3 or Grade 4 neutropenia or thrombocytopenia (see section 4.2 *Dose And Method Of Administration*).

## **Peripheral Neuropathy**

Peripheral neuropathy has been reported in patients treated with Polivy as early as the first cycle of treatment, and the risk increases with sequential doses (see section 4.8 *Undesirable Effects*). Patients with pre-existing peripheral neuropathy may experience worsening of this condition. Peripheral neuropathy reported with Polivy treatment is predominantly sensory peripheral neuropathy; however, motor and sensorimotor peripheral neuropathy have also been reported. Patients should be monitored for symptoms of peripheral neuropathy such as hypoesthesia, hyperesthesia, paresthesia, dysesthesia, neuropathic pain, burning sensation, weakness, or gait disturbance. Patients experiencing new or worsening peripheral neuropathy may require a delay, dose reduction, or discontinuation of Polivy (see section 4.2 *Dose And Method Of Administration*).

## **Infections**

Serious, life threatening, or fatal infections, including opportunistic infections, such as pneumonia (including *Pneumocystis jirovecii* and other fungal pneumonia), bacteraemia, sepsis, herpes infection, and cytomegalovirus infection have been reported in patients treated with Polivy (see section 4.8 *Undesirable Effects*). Patients should be closely monitored during treatment for signs of bacterial, fungal, or viral infections. Anti-infective prophylaxis should be considered. Polivy and any concomitant chemotherapy should be discontinued in patients who develop serious infections.

## **Progressive Multifocal Leukoencephalopathy (PML)**

PML has been reported with Polivy treatment (see section 4.8 *Undesirable Effects*). Patients should be monitored closely for new or worsening neurological, cognitive, or behavioral changes suggestive of PML. Polivy and any concomitant chemotherapy should be held if PML is suspected and permanently discontinued if the diagnosis is confirmed.

## **Tumour Lysis Syndrome**

Patients with high tumour burden and rapidly proliferative tumour may be at increased risk of tumour lysis syndrome. Appropriate measures in accordance with local guidelines should be taken prior to treatment with Polivy. Patients should be monitored closely for tumour lysis syndrome during treatment with Polivy.

## **Embryo-Foetal Toxicity**

Based on the mechanism of action and nonclinical studies, Polivy can be harmful to the foetus when administered to a pregnant woman. (see section 4.6 *Fertility, Pregnancy And Lactation*). Advise a pregnant woman of the risk to the foetus.

Females of reproductive potential should be advised to use effective contraception during treatment with Polivy and for at least 9 months after the last dose. Male patients with female partners of reproductive potential should be advised to use effective contraception during

treatment with Polivy and for at least 6 months after the last dose (see section 4.6 *Fertility, Pregnancy and Lactation*).

### **Hepatic Toxicity**

Serious cases of hepatic toxicity that were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, have occurred in patients treated with Polivy. Pre-existing liver disease, elevated baseline liver enzymes, and concomitant medications may increase the risk. Liver enzymes and bilirubin level should be monitored (see sections 4.2 *Special Populations* And 5.2 *Pharmacokinetics In Special Populations*).

### **Use in hepatic impairment**

The safety and efficacy of Polivy in patients with AST  $>2.5 \times \text{ULN}$ , ALT  $>2.5 \times \text{ULN}$  or total bilirubin  $>1.5 \times \text{ULN}$  has not been formally studied and these patients are likely to have increased exposure to monomethyl auristatin E (MMAE). The administration of Polivy in patients with moderate or severe hepatic impairment (total bilirubin greater than  $1.5 \times \text{ULN}$ ) should be avoided (see sections 4.2 *Special Populations* and 5.2 *Pharmacokinetics In Special Populations*).

### **Use in renal impairment**

The safety and efficacy of Polivy in patients with CrCL  $<30$  mL/min has not been formally studied (see sections 4.2 *Special Populations* and 5.2 *Pharmacokinetics in Special Populations*).

### **Use in the elderly**

In patients with DLBCL (previously untreated and previously treated) no overall differences in safety or efficacy were observed between patients  $\geq 65$  years of age and younger patients (see sections 4.2 *Special Populations* and 5.2 *Pharmacokinetics In Special Populations*).

### **Paediatric use**

The safety and efficacy of Polivy in children and adolescents below 18 years of age has not been established (see sections 4.2 *Special Populations* and 5.2 *Pharmacokinetics In Special Populations*).

### **Effects on laboratory tests**

No data available.

## ***4.5 Interactions With Other Medicines And Other Forms Of Interactions***

No dedicated clinical drug-drug interaction studies with Polivy in humans have been conducted.

### ***Drug interactions with co-medications that are CYP3A inhibitors, inducers or substrates***

Based on physiological-based pharmacokinetic (PBPK) model simulations of MMAE released from polatuzumab vedotin, strong CYP3A inhibitors (e.g., ketoconazole) may increase the area under the concentration-time curve (AUC) of unconjugated MMAE by 48%. Monitor patients receiving concomitant strong CYP3A inhibitors more closely for signs of toxicities. Strong CYP3A inducers (e.g., rifampin) may decrease the AUC of unconjugated MMAE by 49%.



Unconjugated MMAE is not predicted to alter the AUC of concomitant drugs that are CYP3A substrates (e.g., midazolam).

#### *Drug interactions of rituximab and bendamustine in combination with polatuzumab vedotin*

The pharmacokinetics (PK) of rituximab and bendamustine are not affected by co-administration with Polivy. Concomitant rituximab is associated with increased antibody conjugated MMAE (acMMAE) plasma AUC by 24% and decreased unconjugated MMAE plasma AUC by 37%, based on population PK analysis. No dose adjustment is required.

Bendamustine does not affect acMMAE and unconjugated MMAE plasma AUC.

### **4.6 Fertility, Pregnancy And Lactation**

#### **Fertility**

No dedicated fertility studies in animals have been performed with Polivy. However, results of repeat-dose toxicity in rats indicate the potential for polatuzumab vedotin to impair male reproductive function and fertility. In the 4-week repeat-dose toxicity study in rats with weekly dosing of 2, 6, and 10 mg/kg, dose-dependent testicular seminiferous tubule degeneration with abnormal lumen contents in the epididymis was observed. Findings in the testes and epididymis did not reverse and correlated with decreased testes weight and gross findings of small and/or soft testes at recovery necropsy in males given doses  $\geq 2$  mg/kg.

Although there were no histological abnormalities in female reproductive organs from animal studies, dedicated fertility studies in female animals were not conducted.

#### **Pregnancy**

Polivy is not recommended during pregnancy unless the potential benefit for the mother outweighs the potential risk to the foetus. Polivy can cause foetal harm based on the animal studies and the drug's mechanism of action (see section 5.1 *Pharmacodynamic Properties*).

#### **Breast-feeding**

It is not known whether polatuzumab vedotin is excreted in human breast milk. No studies have been conducted to assess the impact of Polivy on milk production or its presence in breast milk. Since many drugs are excreted in human milk and because of the potential for serious adverse reactions in breastfeeding infants due to Polivy, women should discontinue breastfeeding during Polivy treatment and for at least 3 months after the last dose.

#### **Contraception**

Females of reproductive potential should be advised to use effective contraception during treatment with Polivy and for at least 9 months after the last dose.

Male patients with female partners of reproductive potential should be advised to use effective contraception during treatment with Polivy and for at least 6 months after the last dose.

### **4.7 Effects On Ability To Drive And Use Machines**

Polivy may have a minor influence on the ability to drive and use machines. Infusion related reactions, peripheral neuropathy, fatigue, and dizziness may occur during treatment with Polivy (see section 4.4 *Special Warnings And Precautions For Use* and 4.8 *Undesirable Effects*).

## 4.8 Undesirable Effects

### Clinical Trials

The safety of Polivy has been evaluated in 435 patients in Study GO39942 (POLARIX) and in 151 patients in Study GO29365. The adverse drug reactions (ADRs) described in this section were identified based on the following:

- during treatment and follow-up of previously untreated DLBCL patients from the pivotal clinical trial POLARIX (GO39942), who received Polivy plus R-CHP (n=435) or R-CHOP (n=438). In the Polivy plus R-CHP group, 91.7% of patients received 6 cycles of Polivy versus 88.5% of patients who received 6 cycles of vincristine in the R-CHOP group.
- during treatment and follow-up of previously treated diffuse large B-cell lymphoma (DLBCL) patients (n=151) from the pivotal clinical trial GO29365. This includes run-in phase patients (n=6) and randomized patients (n=39) and extension cohort patients (n=106) who received Polivy in combination with bendamustine and rituximab (BR) compared to randomized patients (n=39) who received BR alone. Patients in the Polivy treatment arm received a median of 5 cycles of treatment while randomized patients in the comparator arm received a median of 3 cycles of treatment.

Adverse Drug Reactions (ADRs) from the clinical trials are listed by MedDRA system organ class (SOC) in Table 3 (previously untreated DLBCL) and Table 4 (previously treated DLBCL).

The most frequently reported ( $\geq 30\%$ ) ADRs (all grades) in patients treated with Polivy in combination with R-CHP for previously untreated DLBCL were peripheral neuropathy, nausea, neutropenia, and diarrhoea. Serious adverse reactions were reported in 23.4% of Polivy plus R-CHP treated patients which included the following that occurred in  $\geq 5\%$  of patients: febrile neutropenia (10.6%) and pneumonia (5.3%).

The ADR leading to treatment regimen discontinuation in  $\geq 1\%$  of patients treated with Polivy in combination with R-CHP for previously untreated DLBCL was pneumonia (1.1%).

The most frequently-reported ( $\geq 30\%$ ) ADRs (all grades) in patients treated with Polivy in combination with BR for previously treated DLBCL were anaemia, thrombocytopenia, neutropenia, diarrhoea, nausea, and peripheral neuropathy. Serious adverse events were reported in 55.6% of Polivy plus BR treated patients which included the following that occurred in  $\geq 5\%$  of patients: febrile neutropenia (9.3%), pyrexia (7.9%), pneumonia (6.6%), and sepsis (6.6%).

The ADRs leading to treatment regimen discontinuation in  $>5\%$  of patients was thrombocytopenia (6.0%) and neutropenia (6.7%).

The following categories of frequency have been used: very common ( $\geq 1/10$ ), common ( $\geq 1/100$  to  $< 1/10$ ), uncommon ( $\geq 1/1,000$  to  $< 1/100$ ), rare ( $\geq 1/10,000$  to  $< 1/1000$ ), very rare ( $< 1/10,000$ ).

**Table 3 Summary of adverse drug reactions occurring in patients with previously untreated DLBCL treated with Polivy in combination with R-CHP**

Adverse drug reactions	Polivy + R-CHP n=435	R-CHOP n=438
------------------------	-------------------------	-----------------

SOC	All grades (%)	Grade 3 or Higher (%)	All grades (%)	Grade 3 or Higher (%)
<b>Infections and Infestations</b>				
Upper respiratory tract infection	16.8	0.5	16	0.5
Pneumonia <sup>a</sup>	8.7	5.1	7.3	5.5
Urinary tract infection	8.3	1.8	7.1	1.1
Herpes virus infection	3.4	0.2	3.2	0.5
Sepsis <sup>a</sup>	2.1	2.1	3.4	3.4
Cytomegalovirus infection	0.7	0.5	0.2	0.2
<b>Blood and Lymphatic System Disorders</b>				
Neutropenia	38.4	34.5	39	36.5
Anaemia	28.7	12	26.9	8.7
Febrile Neutropenia	14.9	14.5	8.7	8.7
Leukopenia	14	9.7	13	9.8
Thrombocytopenia	13.3	5.3	13.2	5
Lymphopenia	6.9	4.6	8.7	5.7
Pancytopenia	0.2	0.2	0	0
<b>Metabolism and Nutrition Disorders</b>				
Decreased appetite	16.6	1.1	14.2	0.7
Hypokalaemia	8.3	1.8	8.9	1.8
Hypoalbuminemia	2.3	0.5	2.5	0
Hypocalcaemia	1.6	0.2	2.3	0.5
<b>Nervous System Disorders</b>				
Peripheral Neuropathy	52.9	1.6	53.9	1.1
Dizziness	8.7	0.2	7.8	0.2
<b>Respiratory, Thoracic and Mediastinal Disorders</b>				
Cough	15.4	0	14.4	0
Dyspnoea	12.9	0.9	10	0.9
Pneumonitis	1.1	0.2	0.7	0
<b>Gastrointestinal Disorders</b>				
Nausea	41.6	1.1	37	0.5
Diarrhoea	30.8	3.9	20.1	1.8
Constipation	28.7	1.1	29	0.2
Abdominal Pain	15.6	1.1	13.9	1.6
Vomiting	15.2	1.1	14.4	0.7

<b>Skin and Subcutaneous Tissue Disorders</b>				
Alopecia	24.4	0	24	0.2
Rash	13.3	0.9	11.2	0
Pruritus	8.3	0	6.4	0.2
Skin infections	6.9	1.1	3	0.7
Dry skin	6	0	2.7	0
<b>Musculoskeletal Disorders</b>				
Myalgia	8.7	0.2	7.3	0.2
Arthralgia	6.2	0	8.4	0
<b>General Disorders and Administration Site Conditions</b>				
Fatigue	25.7	0.9	26.5	2.5
Mucositis	21.8	1.4	19.4	0.5
Pyrexia	15.6	1.4	12.6	0
Asthenia	12.2	1.6	12.1	0.5
Peripheral oedema	11	0.2	9.1	0.2
Chills	4.6	0.2	5.3	0.5
<b>Investigations</b>				
Weight decreased	12.6	0.9	12.1	0.2
Transaminases increased	6.7	0.7	5.7	0.2
Hypophosphataemia	4.8	1.8	2.7	1.4
<b>Injury, Poisoning, and Procedural</b>				
Infusion related reaction <sup>b</sup>	13.3	1.1	16	1.6

<sup>a</sup>ADR associated with fatal outcome

<sup>b</sup>Infusion related reaction ADR is reflective of the combination regimen Pola + R-CHP due to same day administration.

**Table 4 Summary of adverse drug reactions occurring in previously treated DLBCL patients treated with Polivy in combination with BR**

System Order Class/ ADR (MedDRA Preferred Term)	Polivy + bendamustine + rituximab N = 151		Frequency (all grades)	Bendamustine + rituximab N=39		Frequency (all grades)
	All grades (%)	Grade 3 or Higher (%)		All grades (%)	Grade 3 or Higher (%)	
<b>Infections and Infestations</b>						
Pneumonia <sup>a</sup>	14.6	9.3	Very common	17.9	5.1	Very common
Sepsis	10.6	9.9	Very common	10.3	10.3	Very common
Upper respiratory tract infection	9.9	0.7	Common	7.7	0	Common

Herpes virus infection	5.3	0.7	Common	10.3	2.6	Very common
Cytomegalovirus infection	2.1	0.7	Common	2.6	2.6	Common
<b>Blood and Lymphatic System Disorders</b>						
Anaemia	31.8	12.6	Very common	28.2	17.9	Very common
Neutropenia	45.7	40.4	Very common	43.6	35.9	Very common
Thrombocytopenia	32.5	25.8	Very common	33.3	25.6	Very common
Febrile Neutropenia	11.3	10.6	Very common	17.9	17.9	Very common
Leukopenia	15.2	10.5	Very common	23.1	18.0	Very common
Lymphopenia	13.2	12.5	Very common	7.7	7.7	Common
Pancytopenia	3.3	2.0	Common	0	0	Very rare
<b>Metabolism and Nutrition Disorders</b>						
Decreased appetite	25.8	2.6	Very common	20.5	0	Very common
Hypokalaemia	16.5	6.5	Very common	10.3	2.6	Very common
Hypoalbuminemia	6.0	1.3	Common	7.7	0	Common
Hypocalcaemia	5.3	0.7	Common	5.2	0	Common
<b>Nervous System Disorders</b>						
Neuropathy	30.5	0.7	Very common	7.7	0	Common
Peripheral Dizziness	11.3	0	Very common	7.7	0	Common
Peripheral Sensory neuropathy	7.3	0	Common	0	0	Very rare
<b>Respiratory, Thoracic and Mediastinal Disorders</b>						
Cough	15.9	0	Very common	25.6	0	Very common
Pneumonitis	1.3	0	Common	0	0	Very rare
<b>Gastrointestinal Disorders</b>						
Diarrhoea	35.8	4.0	Very common	28.2	5.1	Very common
Nausea	33.1	0.7	Very common	41.0	0	Very common
Constipation	18.5	0	Very common	20.5	2.6	Very common
Vomiting	17.2	2.6	Very common	12.8	0	Very common
Abdominal Pain	17.9	4.6	Very common	17.9	2.6	Very common
Abdominal Pain Upper	7.3	0.7	Common	5.1	0	Common
<b>Skin and Subcutaneous Tissue Disorders</b>						
Pruritis	9.3	0	Common	10.3	2.6	Very common
<b>Musculoskeletal disorders</b>						
Arthralgia	4.0	0	Common	0	0	Very rare
<b>General Disorders and Administration Site Conditions</b>						

Fatigue	26.5	2.0	Very common	35.9	2.6	Very common
Pyrexia	28.5	1.3	Very common	23.1	0	Very common
Asthenia	11.9	2.0	Very common	15.4	0	Very common
Chills	4.6	0	Common	7.7	0	Common
<b>Investigations</b>						
Weight decreased	13.9	0.7	Very common	7.7	2.6	Common
Transaminase elevation	7.3	0.7	Common	0	0	Very rare
Hypophosphatemia	4.0	1.4	Common	2.6	2.6	Common
Lipase increased	4.0	1.4	Common	0	0	Very rare
<b>Injury, Poisoning, and Procedural</b>						
Infusion-related reaction <sup>b</sup>	11.9	2.0	Very common	5.1	0	Common

### *Description of selected adverse drug reactions from clinical trials*

#### *Myelosuppression*

##### Previously untreated DLBCL

0.5% of patients in the Polivy plus R-CHP arm discontinued study treatment due to neutropenia compared to no patients in the R-CHOP arm. Thrombocytopenia events led to discontinuation of treatment in 0.2% of patients in the Polivy plus R-CHP arm and none discontinued treatment in the R-CHOP arm. No patients discontinued treatment due to anaemia in either the Polivy plus R-CHP arm or R-CHOP arm.

##### Previously treated DLBCL

4.0% of patients in the Polivy plus BR arm discontinued Polivy due to neutropenia compared to 2.6% of patients in the BR arm who discontinued treatment due to neutropenia. Thrombocytopenia events led to discontinuation of treatment in 7.9% of patients in the Polivy plus BR arms and 5.1% of patients in the BR arm. No patients discontinued treatment due to anaemia in either the Polivy plus BR arms or BR arm.

#### *Peripheral Neuropathy (PN)*

##### Previously untreated DLBCL

In the Polivy plus R-CHP arm, Grade 1, 2, and 3 PN were reported in 39.1%, 12.2%, and 1.6% of patients, respectively. In the R-CHOP arm, Grade 1, 2, and 3 PN were reported in 37.2%, 15.5%, and 1.1% of patients, respectively. No Grade 4–5 PN were reported in either the Polivy plus R-CHP arm or R-CHOP arm. 0.7% of patients discontinued study treatment in the Polivy plus R-CHP due to PN compared to 2.3% in the R-CHOP arm. 4.6% of patients had study treatment dose reduction due to PN compared to 8.2% in the R-CHOP arm. In the Polivy plus R-CHP arm, the median time to onset of first event of PN was 2.27 months compared to 1.87 months in the R-CHOP arm. 57.8% of patients with PN reported event resolution as of the

clinical cut-off date compared to 66.9% in the R-CHOP arm. The median time to peripheral neuropathy resolution was 4.04 months compared to 4.6 months in the R-CHOP arm.

#### Previously treated DLBCL

In the Polivy plus BR arm, Grade 1 and 2 peripheral neuropathy events were reported in 15.9% and 12.6% of patients, respectively. In the BR arm, Grade 1 and 2 peripheral neuropathy events were reported in 2.6% and 5.1% of patients, respectively. One Grade 3 peripheral neuropathy event was reported in the Polivy plus BR arms and no Grade 3 peripheral neuropathy events were reported in the BR arm. No Grade 4-5 peripheral neuropathy events were reported in either the Polivy plus BR arms or BR arm. 2.6% of patients discontinued Polivy treatment due to peripheral neuropathy and 2.0% of patients had Polivy dose reduction due to peripheral neuropathy. No patients in the BR arm discontinued treatment or had dose reductions due to peripheral neuropathy. In the Polivy plus BR arms, the median onset to first event of peripheral neuropathy was 1.6 months, and 39.1% of patients with peripheral neuropathy events reported event resolution (see 4.4 *Special warnings and precautions for use*).

#### **Infections**

##### Previously untreated DLBCL

Infections, including pneumonia and other types of infections, were reported in 49.7% of patients in the Polivy plus R-CHP arm and 42.7% of patients in the R-CHOP arm. Grade 3-4 infections occurred in 14.0% of patients in the Polivy plus R-CHP arm and 11.2% of patients in the R-CHOP arm. In the Polivy plus R-CHP arm, serious infections were reported in 14.0% of patients and fatal infections were reported in 1.1% of patients. In the R-CHOP arm, serious infections were reported in 10.3% of patients and fatal infections were reported in 1.4% of patients. 7 patients (1.6%) in the Polivy plus R-CHP arm discontinued treatment due to infection compared to 10 patients (2.3%) in the R-CHOP arm.

##### Previously treated DLBCL

Infections, including pneumonia and other types of infections, were reported in 48.3% of patients in the Polivy plus BR arm and 51.3% of patients in the BR arm. In the Polivy plus BR arms, serious infections were reported in 27.2% of patients and fatal infections were reported in 6.6% of patients. In the BR arm, serious infections were reported in 30.8% of patients and fatal infections were reported in 10.3% of patients. Four patients (2.6%) discontinued treatment in the Polivy plus BR arms due to infection compared to 2 patients (5.1%) of patients in the BR arm (see 4.4 *Special warnings and precautions for use*).

#### **Progressive Multifocal Leukoencephalopathy (PML)**

##### Previously untreated DLBCL

No cases of PML were reported with Polivy plus R-CHP or in the R-CHOP arm.

##### Previously treated DLBCL

One case of PML, which was fatal, occurred in a patient treated with Polivy plus bendamustine and obinutuzumab. This patient had three prior lines of therapy that included anti-CD20 antibodies (see 4.4 *Special warnings and precautions for use*).

## ***Hepatic toxicity***

### **Previously untreated DLBCL**

Hepatic toxicity was reported in 10.6% of patients in the Polivy plus R-CHP arm and 7.3% of patients in the R-CHOP arm. In the Polivy plus R-CHP arm, most events were Grade 1–2 (8.7%); Grade 3 events were reported in 1.8% of patients. There were no Grade 4 or 5 events. Serious hepatic toxicity events were reported in 1 patient (0.2%) and were reversible.

In another study, two cases of serious hepatic toxicity (hepatocellular injury and hepatic steatosis) were reported and were reversible (*see 4.4 Special warnings and precautions for use*).

## ***Gastrointestinal Toxicity***

### **Previously untreated DLBCL**

Gastrointestinal toxicity events were reported in 76.1% of patients in the Polivy plus R-CHP arm compared to 71.9% of patients in the R-CHOP arm. Most events were Grade 1–2, and Grade  $\geq 3$  events were reported in 9.7% of patients in the Polivy plus R-CHP arm compared to 8.2% of patients in the R-CHOP arm. The most common gastrointestinal toxicity events were nausea and diarrhoea.

### **Previously treated DLBCL**

Gastrointestinal toxicity events were reported in 72.2% of patients in the Polivy plus BR arms compared to 66.7% of patients in the BR arm. Most events were Grade 1-2, and Grade 3-4 events were reported in 16.5% of patients in the Polivy plus BR arm compared to 12.9% of patients in the BR arm. The most common gastrointestinal toxicity events were diarrhoea and nausea.

## **Laboratory abnormalities**

All identified laboratory abnormalities were reported as ADRs, refer to Tables 3 and 4.

## **Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals in New Zealand are asked to report any suspected adverse events to <https://nzphvc.otago.ac.nz/reporting/>.

## **4.9 Overdose**

There is no information on overdose in human clinical trials. Patients who experience overdose should have immediate interruption of their infusion and be closely monitored.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766) (New Zealand).

# **5. PHARMACOLOGICAL PROPERTIES**

## ***5.1 Pharmacodynamic Properties***



## Mechanism of action

Polatuzumab vedotin is a CD79b-targeted antibody-drug conjugate that preferentially delivers a potent anti-mitotic agent (monomethyl auristatin E, or MMAE) to B-cells, which results in the killing of malignant B-cells. The polatuzumab vedotin molecule consists of MMAE covalently attached to a humanised immunoglobulin G1 (IgG1) monoclonal antibody via a cleavable linker. The monoclonal antibody binds with high affinity and selectivity to CD79b, a cell surface component of the B-cell receptor. CD79b expression is restricted to normal cells within the B-cell lineage (with the exception of plasma cells) and malignant B-cells; it is expressed in > 95% of DLBCL. Upon binding CD79b, polatuzumab vedotin is rapidly internalized and the linker is cleaved by lysosomal proteases to enable intracellular delivery of MMAE. MMAE binds to microtubules and kills dividing cells by inhibiting cell division and inducing apoptosis.

## Clinical trials

### Previously untreated DLBCL:

The efficacy of Polivy was evaluated in an international, multicentre, randomised double-blind, placebo-controlled study (POLARIX, GO39942) in 879 patients with previously untreated DLBCL.

Eligible patients were age 18–80 years, and had IPI score 2-5 and ECOG Performance Status 0–2. Histologies included DLBCL (NOS, ABC, GCB), high-grade B-cell lymphoma (HGBL; NOS, double-hit, triple-hit), and other large B-cell lymphoma subtypes (EBV positive, T-cell rich/histiocyte rich). Patients did not have known CNS lymphoma or peripheral neuropathy > Grade 1.

Patients were randomised 1:1 to receive Polivy plus R-CHP or R-CHOP for six 21-day cycles followed by two additional cycles of rituximab alone in both arms. Patients were stratified by IPI score (2 vs 3–5), presence or absence of bulky disease (lesion  $\geq 7.5$  cm), and geographical region.

Polivy was administered intravenously at 1.8 mg/kg on Day 1 of cycles 1–6. R-CHP or R-CHOP were administered starting on Day 1 of Cycles 1–6 followed by rituximab alone on Day 1 of Cycles 7–8. Dosing in each treatment arm was administered according to the following:

- Polivy + R-CHP arm: Polivy 1.8 mg/kg, rituximab 375 mg/m<sup>2</sup>, cyclophosphamide 750 mg/m<sup>2</sup>, doxorubicin 50 mg/m<sup>2</sup>, and oral prednisone 100 mg/day on days 1-5 of every cycle.
- R-CHOP arm: rituximab 375 mg/m<sup>2</sup>, cyclophosphamide 750 mg/m<sup>2</sup>, doxorubicin 50 mg/m<sup>2</sup>, vincristine 1.4 mg/m<sup>2</sup>, and oral prednisone 100 mg/day on days 1-5 of every cycle.

The two treatment groups were generally balanced with respect to baseline demographics and disease characteristics. The median age was 65 years (range 19 to 80 years), 53.6% of patients were white and 53.8% were male. 43.8% had bulky disease, 38.0% had IPI score 2, 62.0% had IPI score 3–5, and 88.7% had Stage 3 or 4 disease. The majority of patients (84.2%) had DLBCL (including NOS, ABC, and GCB). By gene expression profiling, 25.1% of patients had activated B-cell like (ABC) DLBCL and 40.0% of patients had germinal center B-cell like (GCB) DLBCL.

The primary endpoint of the study was investigator-assessed progression-free survival. The median duration of follow up was 28.2 months. Efficacy results are summarised in Table 5 and in Figure 1.

**Table 5 Summary of efficacy in patients with previously untreated DLBCL from study GO39942 (POLARIX)**

	<b>Polivy + R-CHP N= 440</b>	<b>R-CHOP N= 439</b>
<b>Primary Endpoint</b>		
Progression free survival (PFS) <sup>1)*</sup>		
Number (%) of patients with events	107 (24.3%)	134 (30.5%)
HR (95% CI)	0.73 [0.57, 0.95]	
p-value <sup>3)**</sup>	0.0177	
2-year PFS estimate	76.7	70.2
[95% CI]	[72.65, 80.76]	[65.80, 74.61]
<b>Key Endpoints</b>		
Event-free survival (EFS <sub>eff</sub> ) <sup>1)</sup>		
Number (%) of patients with event	112 (25.5%)	138 (31.4%)
HR [95% CI]	0.75 [0.58, 0.96]	
p-value <sup>3)**</sup>	0.0244	
Objective Response Rate (ORR) at End of Treatment <sup>2)</sup>		
Responders (%) (CR, PR)	376 (85.5%)	368 (83.8%)
Difference in response rate (%) [95% CI]	1.63 [-3.32, 6.57]	
Complete Response (%) (CR) Rate <sup>2)*</sup>		
Responders (%)	343 (78.0%)	325 (74.0%)
Difference in response rate (%) [95% CI]	3.92 [-1.89, 9.70]	
p-value <sup>4)**</sup>	0.1557	
Partial response (%) (PR)	33 (7.5%)	43 (9.8%)
95% CI Clopper-Pearson	[5.22, 10.37]	[7.18, 12.97]

INV: Investigator; BICR: Blinded independent central review; CI: Confidence interval; HR: Hazard ratio; PFS: Progression free survival; EFS<sub>eff</sub>: Event free survival efficacy: used to reflect EFS events that are due to efficacy and defined as time from date of randomization to the earliest occurrence of any of the following: disease progression/relapse, death due to any cause, the primary efficacy reason determined by the investigator, other than disease progression/relapse, that led to initiation of any non-protocol specified anti-lymphoma treatment (NALT), if biopsy was obtained after treatment completion and was positive for residual disease regardless of whether NALT was initiated or not; CMH: Cochran-Mantel-Haenszel.

1) INV-assessed

2) BICR-assessed

3) Log-rank test, stratified


4) CMH chi-squared test

\*Per Lugano 2014 Response Criteria

\*\*Stratified by IPI (2 vs 3-5), presence or absence of bulky disease, geography

The CR rate at the end of treatment was 78% on the Polivy plus R-CHP arm and 74% on the R-CHOP arm. Durability of CR was assessed with disease-free survival (DFS) analysis among the POLIVY plus R-CHP and R-CHOP arm (HR = 0.70, 95% CI [0.50, 0.98]), in patients who achieved a best overall response of CR by investigator assessment while on study, with landmark DFS rates at 1 year after the first documented CR of 90% and 83%, respectively. Duration of response (DOR) was assessed for patients with a best overall response of CR or PR based on investigator assessment, (HR = 0.74, 95% CI [0.56, 0.98]); 84% and 78% of patients were still in remission at 1 year after first documented response.

**Figure 1** Kaplan Meier curve of INV-assessed progression free survival in Study GO39942 (POLARIX)



In an exploratory subgroup analysis of PFS, results were generally in support of the benefit of Polivy + R-CHP (HR<1), though the study was not designed to demonstrate differences in subgroups.

*Patient reported outcomes*

The patient-reported peripheral neuropathy rate was assessed using the FACT/GOG-Ntx questionnaire. Scores range from 0-44 with higher scores reflective of low peripheral neuropathy symptoms and high HRQoL. Patients in both arms reported low levels of peripheral neuropathy at baseline. While on treatment, the majority of increases in peripheral neuropathy (i.e. decreases in score) were smaller in the POLIVY plus R-CHP arm (baseline-adjusted mean range: 0.22 to -2.71) than those in the R-CHOP arm (baseline adjusted mean range: 0.01 to -3.51). Patients in the R-CHOP arm experienced increases in peripheral neuropathy earlier (Cycle 4) than patients in the Polivy plus R-CHP arm (Cycle 6) (see 2.6 Undesirable effects). Upon treatment completion, peripheral neuropathy levels in both arms returned close to baseline levels.

Previously treated DLBCL:

The efficacy of Polivy plus BR was evaluated in an international, multicentre, open-label study (GO29365) which included a randomized cohort (n=80) and an extension cohort (n=106) of patients with previously treated DLBCL.

Eligible patients were not candidates for autologous hematopoietic stem cell transplant (HSCT) and had relapsed or refractory disease after receiving at least one prior systemic chemotherapy regimen. The study excluded patients with prior allogeneic HSCT, central nervous system lymphoma, transformed follicular lymphoma (FL), and grade 3b FL.

Polivy was given intravenously at 1.8 mg/kg administered on Day 2 of Cycle 1 and on Day 1 of Cycles 2-6. Bendamustine was administered at 90 mg/m<sup>2</sup> intravenously daily on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6. Rituximab was administered at 375 mg/m<sup>2</sup> intravenously on Day 1 of Cycles 1-6.

The primary endpoint of the study was complete response (CR) rate at end of treatment (6-8 weeks after day 1 of cycle 6 or last study treatment) as assessed by independent review committee (IRC). Efficacy results are summarized in Table 6-7 and in Figures 2-4.

The two treatment groups were generally balanced with respect to baseline demographics and disease characteristics. The median age was 69 years (range 30 to 86 years) and 71% of patients were white and 66% were male. The majority of patients (98%) had DLBCL not otherwise specified (NOS). Overall, 48% of patients had activated B-cell (ABC) DLBCL and 40% of patients had germinal centre B-cell like (GCB) DLBCL. Primary reasons patients were not candidates for HSCT included age (40%), insufficient response to salvage therapy (26%) and prior transplant failure (20%). The median number of prior therapies was 2 (range: 1-7) with 29% (n=23) receiving one prior therapy, 25% (n=20) receiving 2 prior therapies, and 46% (n=37) receiving 3 or more prior therapies. 80% of patients had refractory disease.

The primary endpoint of the study was complete response (CR) rate at end of treatment (6-8 weeks after day 1 of cycle 6 or last study treatment) as assessed by independent review committee (IRC). Efficacy results are summarized in Table 6-7 and in Figures 2-4.

**Table 6 Summary of efficacy in patients with previously treated DLBCL from study GO29365**

	<b>Polivy + bendamustine + rituximab N= 40</b>	<b>Bendamustine + rituximab N= 40</b>
	<b>Median observation time 42 months</b>	

<b>Primary Endpoint</b>	
Complete Response Rate* (IRC-assessed) at End of treatment**	
Responders (%)	16 (40.0)                      7 (17.5)
Difference in response rate (%) [95% CI]	22.5 [2.6, 40.2]
p-value (CMH chi-squared test***)	0.0261
<b>Key Endpoints</b>	
Overall Survival	
Number (%) of patients with event	26 (65.0)                      29 (72.5)
Median OS (95% CI), months	12.4 (9.0, 32)                      4.7 (3.7, 8.3)
HR [95% CI]	0.42 [0.24, 0.75]
p-value (Log-Rank test, stratified***)	0.0014 <sup>†</sup>
Progression Free survival (INV-assessed)	
Number (%) of patients with event	30 (75.0)                      35 (87.5)
Median PFS (95% CI), months	7.5 (5.0, 17.0)                      2.0 (1.5, 3.7)
HR [95% CI]	0.33 [0.20, 0.56]
p-value (Log-Rank test, stratified***)	<0.0001
Duration of response (INV-assessed)	
Number of patients included in analysis	28                                      13
Number (%) of patients with event	20 (71.4)                      11 (84.6)
Median DOR (95% CI), months	12.7 (5.8, 27.9)                      4.1 (2.6, 12.7)
HR [95% CI]	0.42 [0.19, 0.91]
p-value (Log-Rank test, stratified***)	0.0245
Overall Response Rate* (INV-assessed) at End of Treatment**	
Responders (%) (CR, PR)	19 (47.5)                      7 (17.5)
Difference in response rate (%) [95% CI]	30.0 [9.5, 47.4]
p-value (CMH chi-squared test***)	0.0036
Complete Response (%) (CR)	17 (42.5)                      6 (15.0)
Difference in response rate (%) [95% CI]	27.5 [7.7, 44.7]
p-value (CMH chi-squared test***)	0.0061
Partial Response (%) (PR)	2 (5.0)                                      1 (2.5)
95% CI Clopper-Pearson	[0.6, 16.9]                                      [0.06, 13.2]
Best Overall Response Rate* (INV-assessed)	

Responders (%) [CR, PR]	28 (70.0)	13 (32.5)
Difference in response rate (%) [95% CI]	37.5 [15.6, 54.7]	
Complete Response (%) [CR]	23 (57.5)	8 (20.0)
95% CI Clopper-Pearson	[40.9, 73.0]	[9.1, 35.7]
Partial Response (%) [PR]	5 (12.5)	5 (12.5%)
95% CI Clopper-Pearson	[4.2, 26.8]	[4.2, 26.8]


CMH Cochran-Mantel-Haenszel; OS: Overall survival; NE: Not evaluable; PFS: progression free survival; DOR: Duration of response

\*Per modified Lugano 2014 criteria: Bone marrow confirmation of PET-CT CR required. PET-CT PR required meeting both PET-CT criteria and CT criteria.

\*\*6-8 weeks after day 1 of cycle 6 or last study treatment


\*\*\* Stratification by duration of response to prior therapy ( $\leq 12$  months vs  $> 12$  months)

**Figure 2 Kaplan Meier curve of overall survival in Study GO29365**



No.: number; Pola: Polivy; BR: bendamustine and rituximab; HR: hazard ratio. CI: confidence interval

**Figure 3 Kaplan-Meier curve of INV assessed progression-free survival in Study GO29365**



No.; number; Pola: Polivy; BR: bendamustine and rituximab; HR: hazard ratio. CI: confidence interval

**Results of subgroup analyses**

Results of subgroup analysis of overall survival were consistent with the results seen in the overall DLBCL population (see Figure 4 below).

**Figure 4 Forest plot of Overall survival in Study GO29365**

Baseline Risk Factors	Total n	BR (n=40)		Pola-BR (n=40)		Hazard Ratio	95% Wald CI	Pola-RR	95%
		n	Events	n	Events				
All Patients	80	40	29	40	26	12.4	0.43	(0.25, 0.75)	
Age Group (yr)									
<65	31	14	10	17	11	10.8	0.44	(0.18, 1.08)	
≥65	49	26	19	23	15	13.9	0.42	(0.21, 0.84)	
Sex									
Male	53	25	19	28	20	12.1	0.54	(0.28, 1.02)	
Female	27	15	10	12	6	28.0	0.28	(0.10, 0.78)	
Race									
American Indian or Alaska Native	1	1	1	3.4	-	-	-	-	
Asian	10	4	1	32.0	6	2	0.66	(0.66, 7.54)	
Black or African American	3	-	-	-	3	2	8.4	-	
White	37	31	23	4.7	29	3.7	32.6	0.43	(0.22, 0.81)
Unknown	9	4	4	4.1	5	5	9.0	0.26	(0.05, 1.49)
Baseline ECOG PS									
0 or 1	64	31	22	5.3	33	22	13.9	0.45	(0.25, 0.82)
≥2	14	8	7	1.6	6	4	2.6	0.39	(0.10, 1.51)
Ann Arbor Stage at Study Entry									
Stage I/II	10	4	2	-	6	3	32.0	0.92	(0.15, 5.59)
Stage III/IV	70	36	27	3.9	24	23	11.5	0.38	(0.21, 0.67)
Bulky Disease									
Yes	24	14	12	3.4	10	8	11.8	0.56	(0.23, 1.41)
No	56	26	17	5.9	30	18	13.9	0.43	(0.22, 0.85)
Refractory to Last Prior Anti-Lymphoma Therapy									
Yes	63	33	25	3.8	30	22	9.5	0.43	(0.24, 0.78)
No	17	7	4	13.3	10	4	-	0.45	(0.11, 1.84)
Lines of Prior Anti-Lymphoma Therapy									
1	23	12	8	5.9	11	5	0.26	(0.08, 0.86)	
≥2	57	28	21	3.8	29	21	11.5	0.51	(0.27, 0.94)
Primary Refractory									
Yes	49	28	19	3.7	21	15	7.7	0.54	(0.27, 1.07)
No	31	12	10	6.0	19	11	28.0	0.35	(0.14, 0.85)
IPI at Study Entry									
<3	29	11	6	6.0	18	10	28.0	0.66	(0.24, 1.83)
≥3	51	29	23	3.9	22	16	10.5	0.40	(0.20, 0.78)
Cell-of-origin (central review)									
ABC	39	20	15	4.7	19	13	12.8	0.32	(0.15, 0.70)
GCB	32	17	13	3.8	15	12	8.9	0.57	(0.26, 1.27)
Duration of Response to Prior Anti-Lymphoma Therapy									
>12 MONTHS	14	6	4	13.3	8	3	-	0.41	(0.01, 1.85)
≤12 MONTHS	66	34	25	3.9	32	23	10.5	0.43	(0.24, 0.76)
Extranodal Involvement at Study Entry									
Yes	56	29	22	3.9	27	21	11.5	0.46	(0.25, 0.86)
No	24	11	7	8.4	13	5	-	0.37	(0.12, 1.18)
Prior Bone Marrow Transplant									
Yes	16	6	3	5.9	10	6	13.9	0.73	(0.18, 2.95)
No	64	34	26	4.5	30	20	11.6	0.40	(0.22, 0.73)

ECOG PS: Eastern Cooperative Oncology Group Performance Status; IPI: International Prognostic Index; ABC: activated B-cell; GCB: germinal center B-cell like; Pola: Polivy; BR: bendamustine and rituximab; CI: confidence interval

### Extension cohort (n=106)

The median age was 70 years (range 24 to 94 years) 78% of patients were white and 49% were male. The majority of patients (94%) had DLBCL not otherwise specified (NOS). Overall, 48% of patients had ABC DLBCL and 40% of patients had GCB DLBCL. Primary reasons patients were not candidates for HSCT included age (44%), insufficient response to salvage therapy (29%) and prior transplant failure (14%). The median number of prior therapies was 2 (range: 1-7) with 35% (n=37) receiving one prior therapy, 26% (n=27) receiving 2 prior therapies, and 40% (n=42) receiving 3 or more prior therapies. 76% of patients had refractory disease.

**Table 7 Summary of efficacy in extension cohort with previously treated DLBCL from study GO29365**

	<b>Polivy + bendamustine + rituximab n = 106</b>
	<b>Median observation time 9.7 months</b>
<b>Primary Endpoint</b>	
Complete Response Rate* (IRC-assessed) at End of treatment**	
Responders (%) [95% CI]	42 (39.6) [30.3, 49.6]
<b>Key Endpoints</b>	
Overall Survival	
Number (%) of patients with event	51 (48.1)
Median OS (95% CI), months	11.0 (8.3, 14.2)
Progression Free survival (INV-assessed)	
Number (%) of patients with event	68 (64.2)
Median PFS (95% CI), months	5.5 (4.8, 6.9)



Duration of response (INV-assessed)	
Number of patients included in analysis	66 (62.3)
Number (%) of patients with event	28 (42.4)
Median DOR (95% CI), months	5.9 (4.8, 11.6)
Overall Response Rate* (INV-assessed) at End of Treatment**	
Responders (%) (CR, PR)	45 (42.5) [32.9, 52.4]
Complete Response (%) (CR)	39 (36.8)
95% CI Clopper-Pearson	[27.6, 46.7]
Partial Response (%) (PR)	6 (5.7)
95% CI Clopper-Pearson	[2.1 – 11.9]
Best Overall Response Rate* (INV-assessed)	
Responders (%) [CR, PR] 95% CI Clopper-Pearson	66 (62.3) [52.3, 71.5]
Complete Response (%) [CR]	52 (49.1)
95% CI Clopper-Pearson	[39.2, 59.0]
Partial Response (%) [PR]	14 (13.2%)
95% CI Clopper-Pearson	[7.4, 21.2]

IRC: Independent Review Committee; INV: Investigator; CI: Confidence Interval, HR: Hazard Ratio; CMH Cochran-Mantel-Haenszel; OS: Overall survival; NE: Not evaluable; PFS: progression free survival; DOR: Duration of response

\*Per modified Lugano 2014 criteria: Bone marrow confirmation of PET-CT CR required. PET-CT PR required meeting both PET-CT criteria and CT criteria.

\*\*6-8 weeks after day 1 of cycle 6 or last study treatment

\*\*\* Stratification by duration of response to prior therapy ( $\leq 12$  months vs  $> 12$  months)

### Immunogenicity

As with all therapeutic proteins, there is the potential for an immune response in patients treated with polatuzumab vedotin. In Studies GO39442 (POLARIX) and GO29365, 1.4% (6/427) and 5.2% (12/233) of patients tested positive for antibodies against polatuzumab vedotin, respectively, of which none were positive for neutralizing antibodies. Due to the limited number of anti-polatuzumab vedotin antibody positive patients, no conclusions can be drawn concerning a potential effect of immunogenicity on efficacy or safety.

Immunogenicity assay results are highly dependent on several factors including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications and underlying disease. For these reasons, comparison of incidence of antibodies to polatuzumab vedotin with the incidence of antibodies to other products may be misleading.

### **5.2 Pharmacokinetic Properties**

Antibody-conjugated MMAE (acMMAE) plasma exposure increased dose-proportionally over the 0.1 to 2.4 mg/kg polatuzumab vedotin dose range. After the first 1.8 mg/kg polatuzumab vedotin dose, the acMMAE mean maximum concentration ( $C_{max}$ ) was 803 ( $\pm$  233) ng/mL and the area under the concentration-time curve from time zero to infinity ( $AUC_{inf}$ ) was 1860 ( $\pm$  966) day\*ng/mL. Based on the population PK analysis, Cycle 3 acMMAE AUC increased by approximately 30% over cycle 1 AUC, and achieved more than 90% of the Cycle 6 AUC. The terminal half-life at cycle 6 was approximately 12 days (95% CI of 8.1-19.5 days) for acMMAE.

Exposures of unconjugated MMAE, the cytotoxic component of polatuzumab vedotin, increased dose proportionally over the 0.1 to 2.4 mg/kg polatuzumab vedotin dose range. MMAE plasma concentrations followed formation rate limited kinetics. After the first 1.8 mg/kg polatuzumab vedotin dose, the  $C_{max}$  was 6.82 ( $\pm$  4.73) ng/mL, the time to maximum plasma concentration is approximately 2.5 days, and the terminal half-life is approximately 4 days. Plasma exposures of unconjugated MMAE are <3% of acMMAE exposures. Based on the population PK analysis, there is a decrease of plasma unconjugated MMAE exposure ( $AUC$  and  $C_{max}$ ) after repeated every-three-week dosing.

### **Absorption**

Polivy is administered as an IV infusion. There have been no studies performed with other routes of administration.

### **Distribution**

The population estimate of central volume of distribution for acMMAE was 3.15 L, which approximated plasma volume.

*In vitro*, MMAE is moderately bound (71% - 77%) to human plasma proteins. MMAE does not significantly partition into human red blood cells *in vitro*; the blood to plasma ratio is 0.79 to 0.98.

*In vitro* data indicate that MMAE is a P-gp substrate but does not inhibit P-gp at clinically relevant concentrations.

## Metabolism

Polatuzumab vedotin is expected to undergo catabolism in patients, resulting in the production of small peptides, amino acids, unconjugated MMAE, and unconjugated MMAE related catabolites.

*In vitro* studies indicate that MMAE is a substrate for CYP 3A4/5 but does not induce major CYP enzymes. MMAE is a weak time-dependent inhibitor of CYP3A4/5 but does not competitively inhibit CYP3A4/5 at clinically relevant concentrations.

MMAE does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6.

## Excretion

Based on a population pharmacokinetic analysis, the conjugate (acMMAE) is primarily eliminated by non-specific linear clearance pathway with a value of 0.9 L/day.

*In vivo* studies in rats dosed with polatuzumab vedotin (radiolabel on MMAE) demonstrate that the majority of radioactivity is excreted in faeces and the minority of radioactivity is excreted in urine.

## Pharmacokinetics in Special Populations

### Elderly

Age did not have an effect on the pharmacokinetics of acMMAE and unconjugated MMAE based on population PK analyses with patients aged 19-89 years. No significant difference was observed in the pharmacokinetics of acMMAE and unconjugated MMAE among patients <65 years of age (n=394) and patients ≥65 years of age (n=495)

### Children

No studies have been conducted to investigate the pharmacokinetics of Polivy in paediatric patients (<18 years old).

### Renal Impairment

In patients with mild (CrCL 60-89 mL/min, n=361) or moderate (CrCL 30-59 mL/min, n=163) renal impairment, acMMAE and unconjugated MMAE exposures are similar to patients with normal renal function (CrCL ≥ 90 mL/min, n=356), based on population pharmacokinetic analyses. There are insufficient data to assess the impact of severe renal impairment (CrCL 15-29 mL/min, n=4) on PK. No data are available in patients with end-stage renal disease and/or who are on dialysis (see section 4.2 *Dose And Method Of Administration*).

### Hepatic Impairment

In patients with mild hepatic impairment [AST >1.0 - 2.5×ULN or ALT >1.0 - 2.5×ULN or total bilirubin >1.0 - 1.5×ULN, n=133], acMMAE exposures are similar whereas unconjugated MMAE AUC are not more than 40% higher compared to patients with normal hepatic function (n=737), based on population pharmacokinetic analyses.

There are insufficient data to assess the impact of moderate hepatic impairment (total bilirubin >1.5 - 3×ULN, n=11) on PK. Limited data are available in patients with severe hepatic impairment or liver transplantation (see section 4.2 *Dose and method of administration*).

## 5.3 Preclinical Safety Data

## **Genotoxicity**

No dedicated mutagenicity studies in animals have been performed with Polivy. MMAE was genotoxic in the rat bone marrow micronucleus study through an aneugenic mechanism. This mechanism is consistent with the pharmacological effect of MMAE as a microtubule disrupting agent. MMAE was not mutagenic in the bacterial reverse mutation assay (Ames test) or the L5178Y mouse lymphoma forward mutation assay

## **Carcinogenicity**

No dedicated carcinogenicity studies in animals have been performed with Polivy and/or MMAE

# **6. PHARMACEUTICAL PARTICULARS**

## ***6.1 List Of Excipients***

Succinic acid, sodium hydroxide, sucrose, polysorbate 20.

## ***6.2 Incompatibilities***

Do not mix Polivy with, or administer through the same infusion line, as other medicinal products.

No incompatibilities have been observed between Polivy and IV infusion bags with product contacting materials of polyvinyl chloride (PVC), or polyolefins (PO) such as polyethylene (PE) and polypropylene (PP). In addition, no incompatibilities have been observed with infusion sets or infusion aids with product contacting materials of PVC, PE, polyurethane (PU), polybutadiene (PBD), acrylonitrile butadiene styrene (ABS), polycarbonate (PC), polyetherurethane (PEU), or fluorinated ethylene propylene (FEP), or polytetrafluorethylene (PTFE), or with filter membranes composed of polyether sulfone (PES) or polysulfone (PSU).

## ***6.3 Shelf Life***

### **Unopened vial**

The shelf life of the unopened vial is 30 months at 2°C to 8°C.

### **Stability of reconstituted solution in the vial**

From a microbiological point of view, the reconstituted solution and prepared solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless reconstitution and dilution has taken place in controlled and validated aseptic conditions.

If the solution is not used immediately, refer to Section 6.6 *Special Precautions For Disposal and Other Handling* for detailed instructions and storage times of the reconstituted drug product solution and prepared solution for infusion.

This medicine should not be used after the expiry date (EXP) shown on the pack.

## ***6.4 Special Precautions For Storage***

Store unopened vials at 2°C to 8°C.

Keep vial in the outer carton in order to protect from light.

Do not freeze. Do not shake.

Refer to sections 6.3 and 6.6 for storage of the sterile product that has been reconstituted and diluted in infusion diluent.

### ***6.5 Nature And Contents Of Container***

Polivy is available in a single-use glass vial in a pack size of 1 vial.

### ***6.6 Special Precautions For Disposal and Other Handling***

The release of pharmaceuticals in the environment should be minimised. Medicines should not be disposed of via wastewater and disposal through household waste should be avoided.

The following points should be strictly adhered to regarding the use and disposal of syringes and other medicinal sharps:

- Needles and syringes should never be reused.
- Place all used needles and syringes into a sharps container (puncture-proof disposable container). Unused or expired medicine should be returned to a pharmacy for disposal.

### ***Reconstitution***

1. Using a sterile syringe, slowly inject 1.8 mL of sterile water for injection into the 30 mg Polivy vial or 7.2 mL of sterile water for injection into the 140 mg Polivy vial to yield a single-dose solution containing 20 mg/mL polatuzumab vedotin. Direct the stream toward the wall of the vial and not directly on the lyophilized cake.
2. Swirl the vial gently until completely dissolved. *Do not shake.*
3. Inspect the reconstituted solution for discolouration and particulate matter. The reconstituted solution should appear colourless to slightly brown, clear to slightly opalescent, and free of visible particulates. Do not use if the reconstituted solution is discoloured, cloudy, or contains visible particulates.

From a microbiological point of view, the reconstituted solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless reconstitution has taken place in controlled and validated aseptic conditions.

Chemical and physical in-use stability of the reconstituted solution has been demonstrated for up to 72 hours at 2 °C to 8 °C and up to 24 hours at room temperature (9 °C to 25 °C).

### ***Dilution***

1. Polatuzumab vedotin must be diluted to a final concentration of 0.72 – 2.7 mg/mL in an IV infusion bag with a minimum volume of 50 mL containing 0.9% sodium chloride, 0.45% sodium chloride, or 5% dextrose.
2. Determine the volume of 20 mg/mL reconstituted solution needed based on the required dose:

$$\text{Volume} = \frac{\text{Polivy dose (1.8 or 1.4 mg/kg)} \times \text{patient's weight (kg)}}{\text{Reconstituted vial concentration (20 mg/mL)}}$$

3. Withdraw the required volume of reconstituted solution from the Polivy vial using a sterile syringe and dilute into the IV infusion bag. Discard any unused portion left in the vial.
4. Gently mix the IV bag by slowly inverting the bag. *Do not shake.*
5. Inspect the IV bag for particulates and discard if present.

From a microbiological point of view, the prepared solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

Acceptable chemical and physical stability of the prepared solution for infusion has been demonstrated for the durations listed in Table 8. Discard if storage time exceeds these limits. Do not freeze or expose to direct sunlight.

**Table 8 Durations for which acceptable chemical and physical stability of the prepared solution for infusion have been demonstrated**

Diluent used to prepare solution for infusion	Solution for infusion storage conditions <sup>1</sup>
0.9% Sodium Chloride	Up to 72 hours at 2°C to 8°C or up to 4 hours at room temperature (9°C to 25°C)
0.45% Sodium Chloride	Up to 72 hours at 2°C to 8°C or up to 8 hours at room temperature (9°C to 25°C)
5% Dextrose	Up to 72 hours at 2°C to 8°C or up to 8 hours at room temperature (9°C to 25°C)

<sup>1</sup>To ensure product stability, do not exceed specified storage durations.

Avoid transportation of the prepared solution for infusion as agitation stress can result in aggregation. If the prepared solution for infusion will be transported, remove air from the infusion bag and limit transportation to 30 minutes at 9°C to 25°C or 24 hours at 2°C to 8°C. If air is removed, an infusion set with a vented spike is required to ensure accurate dosing during the infusion. The total storage plus transportation times of the diluted product should not exceed the storage duration specified in Table 8.

The product is for single use in one patient only. Discard any residue.

## **7. MEDICINE SCHEDULE**

Prescription

## **8 SPONSOR**

Roche Products (New Zealand) Limited  
PO Box 109113 Newmarket  
Auckland 1149  
NEW ZEALAND

Medical enquiries: 0800 276 243

## **9 DATE OF FIRST APPROVAL**

19<sup>th</sup> December 2019

## **10 DATE OF REVISION OF THE TEXT**

14<sup>th</sup> December 2023

## **SUMMARY TABLE OF CHANGES**

Section Changed	Summary of new information
6.1	Product name included only
2	Addition of the 30 mg vial.
3	Addition of the 30 mg vial
6.2	Addition of polytetrafluorethylene (PTFE) as a product material that has not shown to be incompatible
6.6	Addition of dilution instructions for 30 mg vial.